Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
SLXN
$1.5
$
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Next Earnings
2026-02-25
Beta
-0.035
Average Volume
Market Cap
Last Dividend
CIK
0002022416
ISIN
KYG1281K1307
CUSIP
G1281K130
CEO
Ilan Hadar
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
11
IPO Date
2024-08-16
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer | Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full speed | GlobeNewsWire | 2025-12-16 08:40:00 |
| Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference | Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management will be attending and presenting at the Noble Capital Markets' 21st Annual Emerging Growth Equity Conference (NobleCon21). | GlobeNewsWire | 2025-11-26 07:30:00 |
| Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer | Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its planned regulatory submissions to Israel and Germany | GlobeNewsWire | 2025-11-25 09:15:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| 4 | 2026-02-23 | 2026-02-23 | View Filing |
| DEF 14A | 2026-02-23 | 2026-02-23 | View Filing |
| S-8 | 2026-02-19 | 2026-02-19 | View Filing |
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| PRE 14A | 2026-02-13 | 2026-02-13 | View Filing |
| 8-K | 2026-02-03 | 2026-02-03 | View Filing |
| 4 | 2026-01-27 | 2026-01-27 | View Filing |
| 8-K | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2025-12-31 | 2025-12-31 | View Filing |
| 4 | 2025-12-31 | 2025-12-31 | View Filing |
| 4 | 2025-12-31 | 2025-12-31 | View Filing |
| 4 | 2025-12-31 | 2025-12-31 | View Filing |
| 4 | 2025-12-31 | 2025-12-31 | View Filing |
| 8-K | 2025-12-16 | 2025-12-16 | View Filing |
| 8-K | 2025-12-02 | 2025-12-02 | View Filing |
| 8-K | 2025-11-25 | 2025-11-25 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| S-3 | 2025-10-31 | 2025-10-31 | View Filing |
| EFFECT | 2025-10-01 | 2025-10-01 | View Filing |
| 8-K | 2025-09-30 | 2025-09-30 | View Filing |
| S-3 | 2025-09-26 | 2025-09-26 | View Filing |
| 8-K | 2025-09-26 | 2025-09-26 | View Filing |
| 8-K | 2025-09-25 | 2025-09-25 | View Filing |
| SC 13D/A | 2025-09-23 | 2025-09-23 | View Filing |
| SC 13G | 2025-09-18 | 2025-09-18 | View Filing |
| SC 13G | 2025-09-17 | 2025-09-17 | View Filing |
| SC 13G/A | 2025-09-15 | 2025-09-15 | View Filing |
| SC 13G | 2025-09-15 | 2025-09-15 | View Filing |
| 8-K | 2025-09-15 | 2025-09-15 | View Filing |
| SC 13G | 2025-09-15 | 2025-09-15 | View Filing |
| 8-K | 2025-09-12 | 2025-09-12 | View Filing |
| 424B4 | 2025-09-12 | 2025-09-12 | View Filing |
| EFFECT | 2025-09-12 | 2025-09-12 | View Filing |
| 8-K | 2025-09-11 | 2025-09-11 | View Filing |
| S-1 | 2025-09-05 | 2025-09-05 | View Filing |
| EFFECT | 2025-09-05 | 2025-09-05 | View Filing |
| 8-K | 2025-09-04 | 2025-09-04 | View Filing |
| 424B3 | 2025-09-04 | 2025-09-04 | View Filing |
| 8-K | 2025-09-02 | 2025-09-02 | View Filing |
| S-1 | 2025-08-26 | 2025-08-26 | View Filing |
| S-8 | 2025-08-20 | 2025-08-20 | View Filing |
| 8-K | 2025-08-20 | 2025-08-20 | View Filing |
| 8-K | 2025-08-19 | 2025-08-19 | View Filing |
| 424B3 | 2025-08-12 | 2025-08-12 | View Filing |
| 424B3 | 2025-08-12 | 2025-08-12 | View Filing |
| 424B3 | 2025-08-12 | 2025-08-12 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| DEFA14A | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| D | 2025-08-11 | 2025-08-11 | View Filing |
| 8-K | 2025-08-01 | 2025-08-01 | View Filing |
| 424B3 | 2025-08-01 | 2025-08-01 | View Filing |
| 424B3 | 2025-08-01 | 2025-08-01 | View Filing |
| 8-K | 2025-07-31 | 2025-07-31 | View Filing |
| DEF 14A | 2025-07-31 | 2025-07-31 | View Filing |
| 8-K | 2025-07-29 | 2025-07-29 | View Filing |
| 8-K | 2025-07-21 | 2025-07-21 | View Filing |
| PRE 14A | 2025-07-21 | 2025-07-21 | View Filing |
| 8-K | 2025-07-16 | 2025-07-16 | View Filing |
| 8-K | 2025-07-14 | 2025-07-14 | View Filing |
| 8-K | 2025-07-09 | 2025-07-09 | View Filing |
| 8-K/A | 2025-07-08 | 2025-07-08 | View Filing |
| 8-K | 2025-07-08 | 2025-07-08 | View Filing |
| DEFA14A | 2025-07-07 | 2025-07-07 | View Filing |
| SC 13D/A | 2025-06-26 | 2025-06-26 | View Filing |
| DEFA14A | 2025-06-23 | 2025-06-23 | View Filing |
| DEF 14A | 2025-06-16 | 2025-06-16 | View Filing |
| PRE 14A | 2025-06-05 | 2025-06-05 | View Filing |
| 8-K | 2025-06-03 | 2025-06-03 | View Filing |
| EFFECT | 2025-05-30 | 2025-05-30 | View Filing |
| 8-K | 2025-05-29 | 2025-05-29 | View Filing |
| POS AM | 2025-05-28 | 2025-05-28 | View Filing |
| 8-K | 2025-05-23 | 2025-05-23 | View Filing |
| 8-K | 2025-05-21 | 2025-05-21 | View Filing |
| 424B3 | 2025-05-13 | 2025-05-13 | View Filing |
| 424B3 | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| SC 13G/A | 2025-05-13 | 2025-05-13 | View Filing |
| SC 13G/A | 2025-05-12 | 2025-05-12 | View Filing |
| 424B3 | 2025-05-06 | 2025-05-06 | View Filing |
| EFFECT | 2025-05-02 | 2025-05-02 | View Filing |
| POS AM | 2025-04-29 | 2025-04-29 | View Filing |
| AW | 2025-04-29 | 2025-04-29 | View Filing |
| AW | 2025-04-29 | 2025-04-29 | View Filing |
| 424B3 | 2025-04-29 | 2025-04-29 | View Filing |
| EFFECT | 2025-04-28 | 2025-04-28 | View Filing |
| POS AM | 2025-04-23 | 2025-04-23 | View Filing |
| 8-K | 2025-04-23 | 2025-04-23 | View Filing |
| POS AM | 2025-04-10 | 2025-04-10 | View Filing |
| POS AM | 2025-04-10 | 2025-04-10 | View Filing |
| EFFECT | 2025-04-02 | 2025-04-02 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Swarm Intelligence Strategy | 30.24% | 0.98 | 39 | 0.45 | 0.34 | 61.43 |
| RSI Overbought Strategy | 23.75% | 1.4 | 6 | 0.86 | 12.44 | 54.94 |
| Bull Bias | 16.17% | 1.06 | 39 | 0.31 | 0.22 | 47.35 |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | x | x | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |